The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely ...
Zacks Investment Research on MSN
INSM stock plummets on sinus study failure, adds new pipeline asset
Shares of Insmed INSM lost nearly 20% in after-market trading on Wednesday after the company announced the failure of a ...
Milestone Pharmaceuticals Inc.’s CARDAMYST nasal spray wins FDA approval for PSVT, but faces tough competition and market ...
The 2025 AAO‐HNSF adult sinusitis guideline, an update of the 2015 guideline, offers evidence-based recommendations on ...
Stocktwits on MSN
MIST stock soars pre-market after FDA approves first commercial product – retail remains bullish, dismisses 'sell the news' concerns
Milestone announced that the FDA approved Cardamyst, a novel nasal spray designed to rapidly resolve episodes of Paroxysmal ...
The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in adults. First treatment for ...
The US FDA has approved etripamil (Cardamyst) nasal spray for the self-administered treatment of acute symptomatic paroxysmal ...
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly ...
Many things can block normal nasal drainage, including excess mucus from allergies or an infection, but experts say there are options to help.
Lots of get-togethers this December? Here's what you can do to get through 'silly season' in tact – and recover as quickly as ...
A South Florida company is helping to bring relief to millions of allergy and sinus sufferers with a new device that takes nasal irrigation to the next level. The region’s warm climate, lush ...
Jonathan B. Jassey, DO, is a private pediatrician at Bellmore Merrick Medical. Dr. Jassey also specializes in treating ADHD, anxiety, depression, OCD, autism and other mental health issues. Post-nasal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results